Published in Horm Metab Res on March 01, 2007
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care (2008) 1.63
Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab (2008) 1.45
Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag (2010) 1.45
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vasc Health Risk Manag (2008) 1.27
Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther (2014) 1.16
Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management. Diabetes Ther (2011) 1.13
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healthc Patient Saf (2010) 1.10
Therapy in the early stage: incretins. Diabetes Care (2011) 1.08
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vasc Health Risk Manag (2012) 1.07
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care (2012) 1.04
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag (2011) 1.00
Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr Obes (2009) 0.98
Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag (2013) 0.94
Vildagliptin: a new oral treatment for type 2 diabetes mellitus. Vasc Health Risk Manag (2008) 0.93
Incretin agents in type 2 diabetes. Can Fam Physician (2010) 0.92
The role of incretin therapy at different stages of diabetes. Rev Diabet Stud (2011) 0.89
Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes mellitus. Mayo Clin Proc (2010) 0.89
Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. Vasc Health Risk Manag (2012) 0.87
Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan. World J Diabetes (2013) 0.87
Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. Diabetes Metab J (2011) 0.86
Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis. Diabetes Ther (2013) 0.85
Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes. Diabetes Obes Metab (2015) 0.80
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag (2008) 0.79
A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy. Saudi Pharm J (2013) 0.79
Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability. Ther Clin Risk Manag (2013) 0.79
A 16-week study to compare the effect of vildagliptin versus gliclazide on postprandial lipoprotein concentrations and oxidative stress in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetol Metab Syndr (2015) 0.79
A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation. Trials (2010) 0.79
DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety. Rev Diabet Stud (2007) 0.79
Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study. Diabetes Ther (2014) 0.79
Mechanism of Lipid-lowering Action of the DPP-4 inhibitor, Anagliptin, in LDLR-deficient Mice. J Diabetes Investig (2016) 0.78
The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? J Diabetes Res (2015) 0.78
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Metab Syndr (2014) 0.78
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid (2008) 0.78
Predictive clinical parameters and glycemic efficacy of vildagliptin treatment in korean subjects with type 2 diabetes. Diabetes Metab J (2013) 0.78
DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes. Vasc Health Risk Manag (2017) 0.78
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. Diabetes Metab J (2016) 0.77
Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease. Clinicoecon Outcomes Res (2015) 0.76
Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. CMAJ Open (2017) 0.75
Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes. Clin Med Ther (2009) 0.75
The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis. Br J Clin Pharmacol (2016) 0.75
Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis. BMC Pharmacol Toxicol (2016) 0.75
Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting. J Diabetes Metab Disord (2015) 0.75
Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes. Diabetes Metab Syndr Obes (2009) 0.75
Effect of race and ethnicity on vildagliptin efficacy: a pooled analysis of phase II and III studies. Diabetes Obes Metab (2016) 0.75
Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials. Eur J Clin Pharmacol (2014) 0.75
Microtubule-dependent retrograde transport of proteins into the ER in the presence of brefeldin A suggests an ER recycling pathway. Cell (1990) 9.19
Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med (1993) 6.89
Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia (2000) 3.63
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia (2012) 2.53
The targeting of Lamp1 to lysosomes is dependent on the spacing of its cytoplasmic tail tyrosine sorting motif relative to the membrane. J Cell Biol (1996) 2.32
The endoplasmic reticulum-Golgi intermediate compartment. Curr Opin Cell Biol (1992) 2.18
Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene. J Bacteriol (1988) 2.13
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia (2007) 2.01
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia (2006) 1.89
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab (2011) 1.87
Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Invest (1987) 1.83
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab (2005) 1.76
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab (2010) 1.76
A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia (1995) 1.70
The recycling pathway of protein ERGIC-53 and dynamics of the ER-Golgi intermediate compartment. J Cell Sci (1998) 1.65
An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials. Diabetes Obes Metab (2010) 1.59
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab (2008) 1.58
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab (2007) 1.58
Mechanism of insulin-resistant glucose transport activity in the enlarged adipose cell of the aged, obese rat. J Clin Invest (1982) 1.51
Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia (2005) 1.51
In vitro insulin resistance of human adipocytes isolated from subjects with noninsulin-dependent diabetes mellitus. J Clin Invest (1983) 1.50
Two related strains of feline infectious peritonitis virus isolated from immunocompromised cats infected with a feline enteric coronavirus. J Clin Microbiol (1996) 1.46
Corrective osteotomy of distal radial deformities: a new method of guided locking fixed screw positioning. J Hand Surg Eur Vol (2011) 1.44
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab (2010) 1.43
Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med (2007) 1.43
Amplification of ehrlichial DNA from dogs 34 months after infection with Ehrlichia canis. J Clin Microbiol (1998) 1.42
Influence of duration of lateral decubitus on the spread of hyperbaric tetracaine during spinal anesthesia: a prospective time-response study. Anesth Analg (1994) 1.42
Circulatory failure after anesthesia induction in a patient with severe primary pulmonary hypertension. Anesthesiology (1999) 1.40
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab (2011) 1.38
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med (2008) 1.37
Comparison of the nucleotide sequences of 16S rRNA, 444 Ep-ank, and groESL heat shock operon genes in naturally occurring Ehrlichia equi and human granulocytic ehrlichiosis agent isolates from Northern California. J Clin Microbiol (2000) 1.36
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab (2008) 1.33
Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab (2011) 1.32
Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21--q23 and is associated with a common polymorphism in LMNA in Pima Indians. Mol Genet Metab (2001) 1.32
Relationship between obesity and maximal insulin-stimulated glucose uptake in vivo and in vitro in Pima Indians. J Clin Invest (1984) 1.32
Canine granulocytic anaplasmosis: a review. J Vet Intern Med (2009) 1.29
A determinant in the cytoplasmic tail of the cation-dependent mannose 6-phosphate receptor prevents trafficking to lysosomes. J Cell Biol (1995) 1.28
Common virus infections in cats, before and after being placed in shelters, with emphasis on feline enteric coronavirus. J Feline Med Surg (2004) 1.27
Rate-limiting steps for insulin-mediated glucose uptake into perfused rat hindlimb. Am J Physiol (1986) 1.25
The regulation of glucose transport by cAMP stimulators via three different mechanisms in rat and human adipocytes. J Biol Chem (1983) 1.23
Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab (2007) 1.22
Single lung transplantation for adult respiratory distress syndrome after paraquat poisoning. Thorax (1998) 1.20
Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Horm Metab Res (2008) 1.19
Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab (2001) 1.19
Aortic valve endocarditis in a dog due to Bartonella clarridgeiae. J Clin Microbiol (2001) 1.18
The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract Suppl (2008) 1.17
Molecular consequences of truncations of the first exon for in vitro splicing of yeast actin pre-mRNA. Nucleic Acids Res (1988) 1.16
Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning, sequence, and expression in Escherichia coli. J Bacteriol (1989) 1.16
Seasonal succession of ciliates in lake constance. Microb Ecol (1991) 1.14
Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren. Scand J Rheumatol Suppl (1978) 1.12
Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*. Diabetes Obes Metab (2007) 1.11
Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab (2011) 1.11
A sulphonamido-indanone derivative CGP 28237 (ZK 34228), a novel non-steroidal anti-inflammatory agent without gastro-intestinal ulcerogenicity in rats. Drugs Exp Clin Res (1987) 1.11
Perioperative mortality and major cardio-pulmonary complications after lung surgery for non-small cell carcinoma. Eur J Cardiothorac Surg (1999) 1.06
Insulin binding and hexose transport in rat adipocytes. Relation to cell size. Diabetologia (1980) 1.05
Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia (2011) 1.04
Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. Diabetologia (2013) 1.02
Serologic and molecular evidence of Ehrlichia spp. in coyotes in California. J Wildl Dis (2000) 1.02
Improvement in in vitro insulin action after one month of insulin therapy in obese noninsulin-dependent diabetics. Measurements of glucose transport and metabolism, insulin binding, and lipolysis in isolated adipocytes. J Clin Invest (1983) 1.00
Rate-limiting steps of 2-deoxyglucose uptake in rat adipocytes. Biochim Biophys Acta (1980) 1.00
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab (2008) 1.00
Insulin sensitivity in adipocytes from subjects with varying degrees of glucose tolerance. Am J Physiol (1986) 0.97
Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. Diabetes Obes Metab (2014) 0.97
Glucose 6-phosphate effects on deoxyglucose, glucose and methylglucose transport in rat adipocytes. Evidence for intracellular regulation of sugar transport by glucose metabolites. Biochim Biophys Acta (1984) 0.97
Intracellular glucose concentration in small and large rat adipose cells. Am J Physiol (1980) 0.95
Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res (2007) 0.95
Regulation of plasma lactate concentration in resting human subjects. Metabolism (1990) 0.95
Accumulation of 2-deoxyglucose against its concentration gradient in rat adipocytes. Biochim Biophys Acta (1981) 0.94
Glucose transport in isolated rat adipocytes with measurements of L-arabinose uptake. Am J Physiol (1978) 0.94
Role of vildagliptin in managing type 2 diabetes mellitus in the elderly. Curr Med Res Opin (2010) 0.93
Effect of beta-blockers on exercise double product (systolic blood pressure x heart rate). Br J Clin Pharmacol (1979) 0.93
Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care (2001) 0.92
Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. Am J Physiol (1998) 0.92
Effects of dietary composition on glucose metabolism in rat adipose cells. Am J Physiol (1981) 0.91
A new family of orphan G protein-coupled receptors predominantly expressed in the brain. FEBS Lett (1998) 0.91
XCE, a new member of the endothelin-converting enzyme and neutral endopeptidase family, is preferentially expressed in the CNS. Brain Res Mol Brain Res (1999) 0.91
Acarologic risk of exposure to emerging tick-borne bacterial pathogens in a semirural community in northern California. Vector Borne Zoonotic Dis (2001) 0.90
Stereological changes in the capillary network and nerve cells of the aging human brain. Mech Ageing Dev (1981) 0.90
Bartonella henselae antibody prevalence in free-ranging and captive wild felids from California. J Wildl Dis (1998) 0.89
Interleukin-5 mRNA stability in human T cells is regulated differently than interleukin-2, interleukin-3, interleukin-4, granulocyte/macrophage colony-stimulating factor, and interferon-gamma. Am J Respir Cell Mol Biol (1998) 0.88
Studies in rodents with the dipeptidyl peptidase-4 inhibitor vildagliptin to evaluate possible drug-induced pancreatic histological changes that are predictive of pancreatitis and cancer development in man. Diabetes Obes Metab (2012) 0.88
Pharmacology of diclofenac sodium. Am J Med (1986) 0.88
Estimates of in vivo insulin action in humans: comparison of the insulin clamp and the minimal model techniques. Horm Metab Res (1985) 0.88
Opposite effects of a beta-adrenergic agonist and a phosphodiesterase inhibitor on glucose transport in isolated human adipocytes: isoproterenol increases Vmax and IBMX increases Ks. Biochem Biophys Res Commun (1982) 0.88
Comparison of body composition, adipocyte size, and glucose and insulin concentrations in Pima Indian and Caucasian children. Metabolism (1987) 0.88
Improved insulin action in muscle, liver, and adipose tissue in physically trained human subjects. Am J Physiol (1987) 0.88
Dissociation of in vitro sensitivities of glucose transport and antilipolysis to insulin in NIDDM. Am J Physiol (1987) 0.88
Presentation of a new method for specific measurement of in vivo insulin-stimulated glucose disposal in humans: comparison of this approach with the insulin clamp and minimal model techniques. J Clin Endocrinol Metab (1985) 0.87
Feline inflammatory polyps: historical, clinical, and PCR findings for feline calici virus and feline herpes virus-1 in 28 cases. J Feline Med Surg (2002) 0.86
The effects of short-term overfeeding on adipocyte metabolism in Pima Indians. Metabolism (1985) 0.86
Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro. Am J Physiol (1990) 0.85
Sex difference in insulin-stimulated glucose transport in rat and human adipocytes. Am J Physiol (1984) 0.85